Skip to main content
SpringerLink
Log in

Monoclonal antibodies in cancer therapy

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55:5296

    Google Scholar 

  2. Baselga J, Fan Z, Norton L, Mendelsohn J (1994) Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotheapeutic agents. Ann Oncol 5 [Suppl 5]:abstr no. 010

  3. Baselga J, Mendelsohn J (1994) Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64:127

    Google Scholar 

  4. Baselga J, Norton L, Masui H, et al (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327

    Google Scholar 

  5. Baselga J, Tripathy D, Mendelsohn J, et al (1996) Phase II study of weekly intravenous recombinant humanized anti-P185 (HER2) monoclonal antibody in patients with HER2/NEU overexpressing metasta breast carcinoma. J Clin Oncol 14:737

    Google Scholar 

  6. Bikfalvi A (1995) Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer 31A:1101

    Google Scholar 

  7. Caron P, Lai L, Scheinberg D (1995) Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1:63

    Google Scholar 

  8. Chamow S, Ashkenazi A (1996) Immunoadhesins: principles and applications. Trends Biotechnol 14:52

    Google Scholar 

  9. Chester K, Hawkins R (1995) Clinical issues in antibody design. Trends Biotechnol 13:294

    Google Scholar 

  10. Coney LR, Daniel PT, Sanborn D (1994) Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int J Cancer 58:562

    Google Scholar 

  11. Everson TC (1967) The spontaneous regression of cancer. Prog Clin Cancer 3:79

    Google Scholar 

  12. Fagerberg J, Hjelm A, Ragnhammar P, Frodin J, Wigzell H, Mellstedt H (1995) Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55:1824

    Google Scholar 

  13. Fagerberg J, Steinitz M, Wigzell H, Askelsf P, Mellstedt H (1995) Human anti-idiotypic antibodies induced a Immoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92:4773

    Google Scholar 

  14. Fan Z, Masui H, Baselga J, Mendelsohn J (1993) Antitumor effect of anti-EGF receptor monoclonal antibodies is enhanced by combination treatment with cis-platinum. Proc Anna Meet Am Assoc Cancer Res 34:abstr no. A 2037

  15. Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Riethmüller G, Daddona PE (1988) Enhanced Cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res 48:6303

    Google Scholar 

  16. Foon KA, Maluish AE, Abrams PG, et al (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: therapeutic and immunologic results. Am J Med 80:351

    Google Scholar 

  17. Frankel A, FitzGerald D, Siegall C, Press O (1996) Advances in immunotoxin biology and therapy: a summary of the fourth international symposium on immunotoxins. Cancer Res 56:926

    Google Scholar 

  18. Göttlinger HG, Funke I, Johnson JF, Gokel JM, Riethmüller G (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47

    Google Scholar 

  19. Grossbard ML, Press OW, Applebaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibodybased therapies of leukemia and lymphoma. Blood 80:863

    Google Scholar 

  20. Holz E, Gruber R, Riethmüller G (1996) Monoclonal antibodies in cancer therapy: new perspectives after the colorectal carcinoma trial. Clin Immunother 5:214

    Google Scholar 

  21. Knox S (1995) Overview of studies on experimental radioimmunotherapy. Cancer Res [Suppl] 55:5832s

    Google Scholar 

  22. Koprowski H, Herlyn D, Rubeck M, Defreitas M, Sears HF (1984) Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 81:216

    Google Scholar 

  23. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dörken B, Moldenhauer G (1988) Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 167:345

    Google Scholar 

  24. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685

    Google Scholar 

  25. Litvinov S, Velders M, Bakker H, Fleuren G, Warnaar S (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437

    Google Scholar 

  26. Mack M, Riethmüller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021

    Google Scholar 

  27. Maruyama H, Benden A, Li W, et al (1996) Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733. Int J Cancer 65:547

    Google Scholar 

  28. Matzinger P (1994) Tolerance, danger, and the extended family. Ann Rev Immunol 12:991

    Google Scholar 

  29. Mellstedt H, Frödin JE, Masucci G, et al (1991) The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1:462

    Google Scholar 

  30. Melton R, Sherwood R (1996) Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 88:153

    Google Scholar 

  31. Minasian L, Tzy-Jyun-Yao Y, Steffens T, Scheinber D, et al (1995) A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 75:2251

    Google Scholar 

  32. Moertel C, Fleming T, Macdonald J, et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321

    Google Scholar 

  33. Oosterwijk E, Bander N, Divgi C, et al (1993) Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11:738

    Google Scholar 

  34. O'Connell M, Laune J, Shepher L, et al (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the north central cancer treatment group and the national cancer institute of canada clinical trials group. J Clin Oncol ASCO-Meeting:abstr no. 478

  35. Pieteresz GA, McKenzie IFC (1992) Antibody conjugates for the treatment of cancer. Immunol Rev 129:57

    Google Scholar 

  36. Ragnhammar P, Fagerberg J, Frödin JE (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced Int J Cancer 53:751

    Google Scholar 

  37. Ranghammer P, Fagerberg J, Frodin J, Wersall P, Hansson L, Mellstedt H (1995) Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 40:367

    Google Scholar 

  38. Ravetch JV, Kinet J-P (1991) Fe receptors. Annu Rev Immunol 9:457

    Google Scholar 

  39. Rees A, Stauton D, Webster D, Searle S, Henry A, Pedersen J (1994) Antibody design: beyond the natural limits. Trends Biotechnol 12:199

    Google Scholar 

  40. Reiter Y, Pastan I (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 2:245

    Google Scholar 

  41. Riethmüller G, Schneider-Gödicke E, Johnsen JP (1993) Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5:732

    Google Scholar 

  42. Riethmüller G, Schneider-Gödicke E, Schlimok G, et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177

    Google Scholar 

  43. Rivoldni L, Kawakami Y, Sakaguchi K, et al (1995) Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MARTA. J Immunol 154:2257

    Google Scholar 

  44. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180

    Google Scholar 

  45. Rosenberg SA (1993) Principles and applications of biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 293–324

    Google Scholar 

  46. Saga T, Neumann R, Heya T, et al (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92:8999

    Google Scholar 

  47. Saleh M, Khazaeli M, Wheeler R, et al (1995) Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rh-M-CSF) in patients with metastatic gastrointesinal cancer. Cancer Res 55:4330

    Google Scholar 

  48. Santoro L, Reboul A, Kerblat I, Droner C, Colomb M (1996) Monoclonal IgG as antigen: reduction is an early intracellular event of their processing by antigen-presenting cells. Int Immunol 8:211

    Google Scholar 

  49. Schlimok G, Funke I, Holzmann B, et al (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti- cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Med Sci 84:8672

    Google Scholar 

  50. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G (1995) Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 31A:1799

    Google Scholar 

  51. Tai-Ping D, Jaggar R, Bicknell R (1995) Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16:57

    Google Scholar 

  52. Theodoulou M, Gilewski T, Welt S, et al (1994) Anti-Lewis Y (LeY) monoclonal antibody (mAb) BR55-2 (IgG2a) in patients with advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 13:abstr no. A974

  53. Van Den Eynde B, Hainaut P, Herin M, et al (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 44:634

    Google Scholar 

  54. Vitetta E, Thorbe P, Uhr J (1993) Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252

    Google Scholar 

  55. Welt S, Divgi C, Scott A, et al (1994) Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 12:1193

    Google Scholar 

  56. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J (1995) Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897

    Google Scholar 

  57. Zhang S, Helling F, Lloyd K, Linvingston P (1995) Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 40:88

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Immunologie der Ludwig-Maximilians-Universität, Goethestrasse 31, D-80336, München, Germany

    Rudolf Gruben & Gert Riethmüller

  2. Tumorzentrum München an den Medizinischen Fakultäten der Ludwig-Maximilians-Universität und der Technischen Universität München, Germany

    Elena Holz

Authors
  1. Rudolf Gruben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Holz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gert Riethmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gruben, R., Holz, E. & Riethmüller, G. Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol 18, 243–251 (1996). https://doi.org/10.1007/BF00820669

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00820669

Keywords

Search

Navigation